Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ for Metabolic Dysfunction in Obese Asthma
NCT04026711Phase 1Completed
- Sponsor
- The University of Vermont
- Start
- Jan 2020
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mitoquinone in asthma, sponsored by The University of Vermont. Primary endpoint: Change in airway reactivity at 12 weeks. Started Jan 2020; status: completed.
02
Drugs
mitoquinone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04026711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026711.